336 related articles for article (PubMed ID: 27294523)
21. TGFβ signaling limits lineage plasticity in prostate cancer.
Hao Y; Bjerke GA; Pietrzak K; Melhuish TA; Han Y; Turner SD; Frierson HF; Wotton D
PLoS Genet; 2018 May; 14(5):e1007409. PubMed ID: 29782499
[TBL] [Abstract][Full Text] [Related]
22. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
[TBL] [Abstract][Full Text] [Related]
23. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
[TBL] [Abstract][Full Text] [Related]
24. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
25. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway.
Chen J; Chang H; Peng X; Gu Y; Yi L; Zhang Q; Zhu J; Mi M
Sci Rep; 2016 Jun; 6():28858. PubMed ID: 27345219
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
27. A basal-enriched microRNA is required for prostate tumorigenesis in a Pten knockout mouse model.
Fan X; Bjerke GA; Riemondy K; Wang L; Yi R
Mol Carcinog; 2019 Dec; 58(12):2241-2253. PubMed ID: 31512783
[TBL] [Abstract][Full Text] [Related]
28. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
30. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
[TBL] [Abstract][Full Text] [Related]
31. Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.
Alaña L; Sesé M; Cánovas V; Punyal Y; Fernández Y; Abasolo I; de Torres I; Ruiz C; Espinosa L; Bigas A; Y Cajal SR; Fernández PL; Serras F; Corominas M; Thomson TM; Paciucci R
Mol Cancer; 2014 Mar; 13():74. PubMed ID: 24684754
[TBL] [Abstract][Full Text] [Related]
32. Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions.
Pedrosa AR; Trindade A; Carvalho C; Graça J; Carvalho S; Peleteiro MC; Adams RH; Duarte A
Oncotarget; 2015 Sep; 6(27):24404-23. PubMed ID: 26213336
[TBL] [Abstract][Full Text] [Related]
33. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
Hill R; Song Y; Cardiff RD; Van Dyke T
Cancer Res; 2005 Nov; 65(22):10243-54. PubMed ID: 16288012
[TBL] [Abstract][Full Text] [Related]
35. Notch signaling in prostate cancer: refining a therapeutic opportunity.
Su Q; Xin L
Histol Histopathol; 2016 Feb; 31(2):149-57. PubMed ID: 26521657
[TBL] [Abstract][Full Text] [Related]
36. Pten dose dictates cancer progression in the prostate.
Trotman LC; Niki M; Dotan ZA; Koutcher JA; Di Cristofano A; Xiao A; Khoo AS; Roy-Burman P; Greenberg NM; Van Dyke T; Cordon-Cardo C; Pandolfi PP
PLoS Biol; 2003 Dec; 1(3):E59. PubMed ID: 14691534
[TBL] [Abstract][Full Text] [Related]
37. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
[TBL] [Abstract][Full Text] [Related]
38. Notch activation stimulates migration of breast cancer cells and promotes tumor growth.
Bolós V; Mira E; Martínez-Poveda B; Luxán G; Cañamero M; Martínez-A C; Mañes S; de la Pompa JL
Breast Cancer Res; 2013; 15(4):R54. PubMed ID: 23826634
[TBL] [Abstract][Full Text] [Related]
39. The essential role of WD repeat domain 77 in prostate tumor initiation induced by Pten loss.
O'Bryant D; Wang Z
Oncogene; 2018 Jul; 37(30):4151-4163. PubMed ID: 29706654
[TBL] [Abstract][Full Text] [Related]
40. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
